Polycystic ovary syndrome (PCOS) affects up to 10% of women of reproductive age, making it one of the most common endocrine disorders. Beyond the hallmark symptoms of irregular periods, excess androgen production, and ovarian cysts, PCOS is a leading contributor to female infertility. For many women with PCOS, conventional ovulation induction and assisted reproductive technologies (ART) are the standard approach, but complementary strategies are gaining attention. Among these, melatonin—a hormone best known for its role in sleep regulation—has emerged as a promising adjunct to improve fertility outcomes. This article explores the biological rationale, clinical evidence, and practical considerations for using melatonin to enhance fertility in women with PCOS, with a focus on oxidative stress, oocyte quality, and hormonal balance.

Understanding Melatonin: More Than a Sleep Hormone

What Is Melatonin?

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesized primarily in the pineal gland from the amino acid tryptophan, following a circadian rhythm that peaks at night. Its primary function is to synchronize the body's internal clock with the light-dark cycle, facilitating restful sleep. However, melatonin is also produced in several extra-pineal tissues, including the ovaries, where it acts as a potent antioxidant and signaling molecule.

Unlike many hormones that are stored in large quantities, melatonin is released in a pulsatile manner and has a short half-life. Its production declines with age and can be disrupted by shift work, blue light exposure, and chronic stress—all factors that may indirectly affect reproductive health.

Antioxidant and Anti-Inflammatory Properties

One of melatonin's most studied non-sleep roles is its capacity to neutralize free radicals. Melatonin is a direct scavenger of reactive oxygen species (ROS) and reactive nitrogen species, and it also stimulates the activity of endogenous antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, and catalase. This dual mechanism makes melatonin uniquely effective at reducing oxidative stress without becoming pro-oxidant itself—a critical advantage in tissues that are highly sensitive to oxidative damage, such as the ovarian follicle.

Additionally, melatonin exerts anti-inflammatory effects by inhibiting nuclear factor-kappa B (NF-κB) activation and reducing the expression of pro-inflammatory cytokines. Since both oxidative stress and chronic low-grade inflammation are central players in PCOS pathophysiology, melatonin's anti-inflammatory properties may offer further therapeutic benefit.

Melatonin in Reproductive Physiology

Melatonin receptors (MT1 and MT2) are expressed in granulosa cells, theca cells, and the oocyte itself. The hormone is present in follicular fluid at concentrations several times higher than in blood, suggesting active transport and a local role in follicle maturation. Melatonin influences ovarian steroidogenesis, protects the oocyte from ROS during ovulation and fertilization, and may enhance corpus luteum function. In males, it also supports sperm quality, underscoring its broad role in reproduction.

In women with PCOS, the delicate balance of melatonin in the follicular environment may be disturbed. Some studies report altered melatonin levels in serum and follicular fluid, which could contribute to the poor oocyte quality and lower fertilization rates observed in these patients.

PCOS: A Complex Endocrine Disorder

Diagnostic Criteria and Heterogeneity

PCOS is diagnosed using the Rotterdam criteria, which require two of the following three features: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovaries on ultrasound. The disorder presents with significant phenotypic heterogeneity, ranging from lean, insulin-resistant women to obese individuals with severe metabolic disturbances. Regardless of subtype, anovulation and delayed conception remain common.

The root causes of PCOS are multifactorial, involving genetic predisposition, hypothalamic-pituitary axis dysregulation, and peripheral insulin resistance. Elevated luteinizing hormone (LH) drives excess ovarian androgen production, while hyperinsulinemia amplifies the effect. These hormonal disturbances lead to follicular arrest—a state where antral follicles stop growing due to an unfavorable intraovarian environment.

Oxidative Stress and Infertility in PCOS

There is strong evidence that women with PCOS have higher systemic levels of oxidative stress markers (e.g., malondialdehyde, 8-hydroxydeoxyguanosine) and lower antioxidant capacity (e.g., reduced glutathione, vitamin C) compared to eumenorrheic controls. Within the ovary, increased ROS levels damage the oocyte's DNA, impair mitochondrial function, and accelerate granulosa cell apoptosis. This oxidative milieu contributes to:

  • Poor oocyte maturation and reduced fertilization rates
  • Lower embryo quality and cleavage rates
  • Increased risk of miscarriage
  • Exacerbation of insulin resistance and inflammation

Thus, any intervention that reduces oxidative stress in the ovarian follicle has the potential to improve fertility. Melatonin, with its high bioavailability to the follicle and strong antioxidant profile, is a logical candidate.

The Mechanism: How Melatonin May Help PCOS Fertility

Reducing Oxidative Stress in Follicles

In the ovarian follicle, melatonin acts both directly and indirectly to lower ROS levels. By scavenging hydroxyl radicals and singlet oxygen, it protects the cumulus-oocyte complex from lipid peroxidation. It also upregulates antioxidant enzymes that are often suppressed in PCOS granulosa cells. Animal studies show that melatonin supplementation increases follicular fluid antioxidant capacity and reduces markers of oxidative damage, leading to healthier follicles and more competent oocytes.

In women undergoing IVF, follicular fluid melatonin levels correlate positively with oocyte maturity and embryo quality. Women with PCOS who have lower follicular melatonin tend to have worse outcomes. These observations suggest that correcting the intrafollicular redox balance with exogenous melatonin could be clinically beneficial.

Improving Oocyte Quality and Embryo Development

Oocyte quality is the single most important determinant of embryo development and implantation. Melatonin supports meiotic spindle formation, prevents spindle abnormalities, and reduces fragmentation in developing embryos. In a study on mouse oocytes, melatonin treatment improved blastocyst formation rates and increased the expression of genes related to embryonic development. Translating this to humans, a randomized controlled trial found that women with PCOS who received melatonin (3 mg daily) before and during gonadotropin stimulation had higher rates of mature oocytes (MII) and better day-3 embryo morphology than those given placebo.

Hormonal Modulation

Beyond antioxidant effects, melatonin influences the hypothalamic-pituitary-ovarian (HPO) axis. It can suppress LH secretion and reduce the LH/FSH ratio—a common abnormality in PCOS that perpetuates anovulation. Melatonin may also improve insulin sensitivity by acting on melatonin receptors in pancreatic beta-cells and adipose tissue. Hyperinsulinemia is a key driver of ovarian androgen excess, so any improvement in insulin resistance could ameliorate hyperandrogenism and restore ovulation. Preliminary data from small studies show that melatonin supplementation reduces total testosterone and free androgen index in women with PCOS.

Clinical Evidence and Research Findings

Key Studies on Melatonin and PCOS Fertility

The clinical literature on melatonin for PCOS is growing but still limited. Several randomized controlled trials have been conducted:

  • Rizzo et al. (2018) – A pilot study on 40 women with PCOS undergoing IVF: 3 mg melatonin nightly starting 6 weeks before the cycle until embryo transfer. Results showed significantly more mature oocytes and higher clinical pregnancy rates in the melatonin group (37% vs. 18%).
  • Shafiee et al. (2020) – A double-blind trial involving 60 PCOS patients: 10 mg melatonin daily for 2 months improved ovulatory function and reduced menstrual cycle length. Ferriman-Gallwey scores (hirsutism) also decreased.
  • Mokhtari et al. (2021) – Combined metformin and melatonin supplementation in PCOS women with insulin resistance. The group receiving both agents had significantly better improvements in fasting insulin, HOMA-IR, and menstrual regularity compared to metformin alone.
  • Taghizadeh et al. (2022) – A meta-analysis of 7 trials concluded that melatonin supplementation significantly improved oocyte maturity rate and reduced oxidative stress biomarkers in PCOS patients undergoing ART. However, the authors noted heterogeneity in dosage and treatment duration.

Overall, the evidence supports melatonin's potential to enhance both natural and assisted conception in PCOS, but most studies are small-scale. Larger, multicenter trials with standardized protocols are needed to confirm the optimal dose and treatment window.

Melatonin Supplementation in Assisted Reproductive Technology

For women with PCOS who pursue in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), melatonin is often used as an adjuvant to improve oocyte retrieval outcomes. Protocols typically involve 3–6 mg of melatonin taken at bedtime, beginning 4–6 weeks before ovarian stimulation. This timing allows the antioxidant to accumulate in follicular fluid and exert its protective effect during the critical period of oocyte growth and maturation.

Some clinics also administer melatonin during the luteal phase in frozen-thawed embryo transfers, hypothesizing that it supports endometrial receptivity by reducing local oxidative stress. While the evidence for this application is less robust, early results are promising. For women with PCOS who have previously failed IVF cycles with poor oocyte quality, melatonin supplementation may be a low-risk intervention worth considering.

In natural conception, melatonin combined with lifestyle interventions (diet, exercise, stress reduction) may help restore ovulation. Case reports describe women with PCOS who resumed regular cycles after 3–4 months of melatonin therapy, although spontaneous pregnancy rates need further study.

Practical Considerations: Using Melatonin Supplements

Dosage and Timing

Melatonin is available over the counter in doses ranging from 0.5 mg to 10 mg. For fertility purposes, the most commonly studied doses are 3–5 mg per day, taken 30–60 minutes before bedtime to mimic the natural nocturnal surge. Starting with a low dose (1–3 mg) and adjusting upward based on tolerance and response is generally recommended. Splitting the dose is not advised, as it may disrupt circadian signaling.

Timing is crucial: melatonin's effectiveness depends on consistent administration at the same time each evening. Irregular dosing can desynchronize the circadian clock and may even worsen ovarian function. Women who work night shifts or have irregular sleep schedules should consult a sleep specialist before initiating melatonin.

It is important to note that melatonin supplements are not FDA-approved for fertility treatment, so they are used off-label. Patients should purchase from reputable brands that undergo third-party testing to ensure purity and dosage accuracy.

Safety and Side Effects

Melatonin is generally well-tolerated. Common side effects include drowsiness, headache, dizziness, and mild gastrointestinal upset. These are usually transient and dose-dependent. Less common effects include vivid dreams, daytime grogginess (if taken too late or at excessive doses), and interactions with blood pressure or anticoagulant medications.

Potential concerns specific to PCOS include:

  • Effect on prolactin: Some animal studies suggest melatonin can stimulate prolactin secretion, which could counteract fertility efforts. In human trials, prolactin remained within normal ranges, but women with a history of hyperprolactinemia should be monitored.
  • Impact on thyroid function: Melatonin may modestly suppress thyroid-stimulating hormone (TSH). Since hypothyroidism can mimic or worsen PCOS, baseline thyroid function should be checked.
  • Use during pregnancy: Safety data are limited. Most fertility protocols discontinue melatonin once a positive pregnancy test is confirmed, although some studies continued through the first trimester without adverse effects. Women should discuss with their obstetrician.

Interaction with Other PCOS Treatments

Melatonin is frequently used alongside metformin, the first-line medication for PCOS-related insulin resistance. As noted, the combination may offer synergistic benefits on metabolic and reproductive parameters. Similarly, melatonin can complement clomiphene citrate or letrozole for ovulation induction, though no formal interaction studies exist.

Women who take oral contraceptives for cycle regulation may have altered melatonin metabolism, as estrogen influences tryptophan availability. Those planning a pregnancy who decide to stop OCPs may benefit from melatonin during the transition to restore natural cycling.

For patients undergoing IVF, melatonin is added to the stimulation protocol, not as a replacement. It does not interfere with gonadotropins, GnRH agonists/antagonists, or progesterone support. However, because melatonin can cause daytime drowsiness at higher doses, women should take it only at night to avoid impairing daytime functioning during the demanding IVF cycle.

Conclusion

Melatonin represents a promising, low-cost, and relatively safe adjunct for improving fertility in women with PCOS. Its dual action—antioxidant protection of the oocyte and modulation of the HPO axis—addresses two key pathophysiological features of the condition: oxidative stress and hormonal dysregulation. Clinical evidence, though still evolving, points to improved oocyte quality, higher pregnancy rates, and better metabolic profiles with melatonin supplementation.

While melatonin is not a standalone treatment for PCOS-related infertility, it may be a valuable tool when integrated into a comprehensive plan that includes lifestyle modification, conventional ovulatory agents, and, when needed, ART. The strongest evidence supports its use during the 4–8 weeks preceding ovarian stimulation for IVF, but benefits may also extend to natural conception when cycles are irregular.

As with any supplementation, patient selection and medical supervision are essential. Women with PCOS who are considering melatonin should discuss it with a reproductive endocrinologist or fertility specialist, especially if they have comorbidities such as thyroid disease, autoimmune conditions, or are taking other medications. Future research should aim to establish optimal dosing regimens, long-term safety in PCOS populations, and potential benefits for specific phenotypes.

For further reading on the role of oxidative stress in PCOS, see the comprehensive review by DOI: 10.1007/s43032-017-0008-5. Clinical trial data on melatonin in ART can be accessed via ClinicalTrials.gov. The Endocrine Society also offers patient-friendly resources on PCOS management. Women seeking personalized advice should consult their healthcare provider.